Needham analyst Ami Fadia has maintained their neutral stance on SAGE stock, giving a Hold rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ami Fadia has given his Hold rating due to a combination of factors related to SAGE Therapeutics’ recent performance and future prospects. The company reported a 21% increase in prescriptions for its drug Zurzuvae in the fourth quarter of 2024 compared to the previous quarter. However, sales did not meet expectations due to inventory adjustments, despite management’s plans to increase investments in collaboration with Biogen.
Additionally, SAGE Therapeutics is exploring strategic alternatives, adding an element of uncertainty. While management’s comments on Zurzuvae’s market uptake and promotional efforts are positive, the company remains in a transitional phase. The decision to maintain a Hold rating reflects a cautious approach as analysts await more clarity on the company’s strategic direction and product pipeline developments, such as the SAGE-319 and SAGE-324 programs and potential regulatory approvals in Japan.
In another report released today, H.C. Wainwright also maintained a Hold rating on the stock with a $12.00 price target.